Lawmakers push to end drug ads targeting consumers

Prescription drug advertising has never had it easy, but lately the $4.3 billion ad sector has come under attack from lawmakers who are trying to get the ads off the airwaves. Some congressmen are targeting complicated ads that promote a drug to address a malady that you may not know you have. As Washington tries to reach agreement on a sweeping overhaul of health care, direct-to-consumer advertising, or DTC, is being targeted as a contributor to the high cost of health care. Nonetheless, lawmakers want to rid the airwaves of them. Rep. James Moran (D-VA) wants them eliminated on the grounds of decency standards. Rep Henry Waxman (D-CA) wants drugmakers to refrain from advertising them for a certain period of time after receiving market approval from the Food and Drug Administration. Others, including Rep Jerrold Nadler (D-NY), want to amend the federal tax code to bar pharmaceutical companies from deducting the cost of the ads as a business expense. Potential legislation comes at a time when the sector has pulled back on spending and faces greater scrutiny from the FDA, which already imposes strong guidelines on what is allowed in the ads. Ad experts say the ads won't disappear because they work, are already regulated and don't add to the cost of health care.